Trophic Effects of Aldosterone

Renin Angiotensin System and the Heart

Volumn , Issue , 2006, Pages 161-177

  Delcayre, Claude ^a   Heymes, Christophe ^a   Milliez, Paul ^a   Swynghedauw, Bernard ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Aldosterone trophic effect; Aldosterone induced fibrosis; Aldosterone synthase (AS); Cardiac aldosterone synthesis; Cardiac remodeling; Collagen metabolism; Plasma aldosterone concentration; RALES trial

Indexed keywords

EID: 84954594664     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470032103.ch11     Document Type: Chapter

References (51)

1. Anand IS (1997) Pathogenesis of salt and water retention in the congestive heart failure syndrome. In Heart Failure. Scientific Principles and Clinical Practice, Poole-Wilson PA, Colucci WS, Massie BM, et al. (eds), Churchill Livingstone, New York, pp. 155-171.
2. Beggah AT, Escoubet B, Puttini S, et al. (2002) Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proceedings of the National Academy of Sciences of the United States of America 99, 7160-7165.
3. 2+ current in adult rat cardiomyocytes. Circulation Research 85, 1139-1145.
4. Brilla CG, Pick R, Tan LB, et al. (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circulation Research 67, 1355-1364.
5. Casal AJ, Silvestre JS, Delcayre C and Capponi AM (2003) Expression and modulation of the steroidogenic acute regulatory (StAR) protein mRNA in rat cardiocytes and after myocardial infarction. Endocrinology 144, 1861-1868.
6. Delcayre C and Swynghedauw B (2002) Molecular mechanisms of myocardial remodeling. The role of aldosterone. Journal of Molecular and Cellular Cardiology 34, 1577-1584.
7. Dell'Italia LI, Meng QC, Balcells E, et al. (1997) Compartimentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. Journal of Clinical Investigation 100, 253-258.
8. De Mello WC (2002) Aldosterone modulates the effect of angiotensin II on the electrical properties of rat heart. Journal of Cardiovascular Pharmacology 40, 90-95.
9. De Mello WC and Danser AH (2000) Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension 35, 1183-1188.
10. Farman N and Rafestin-Oblin ME (2001) Multiple aspects of mineralocorticoid selectivity. American Journal of Physiology. Renal Physiology 280, F181-F192.
11. Farquharson CAJ and Struthers AD (2000) Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and supresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101, 594-597.
12. Funder JW (1997) Glucocorticoid and mineralocorticoid receptors. Biology and clinical relevance. Annual Reviews of Medicine 448, 231-240.
13. Funder JW, Pearce PT, Smith R and Smith AI (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242, 583-585.
14. Gomez-Sanchez CE, Zhou MY, Cozza EN, et al. (1997) Aldosterone biosynthesis in the rat brain. Endocrinology 138, 3369-3373.
15. Hatakeyama H, Miyamori I, Fujita T, et al. (1994) Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. Journal of Biology Chemistry 269, 24316-24320.
16. Horisberger JD and Rossier BC (1992) Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 19, 221-227.
17. van Kats JP, Duncker DJ, Haitsma DB, et al. (2000) Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 102, 1556-1563.
18. Lacolley P, Safar ME, Lucet B, et al. (2001) Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. Journal of the American College of Cardiology 37, 662-667.
19. Lacolley P, Labat C, Pujol A, et al. (2002) Increased carotid wall elastic modulus and fibronectin in aldosterone-salt treated rats. Effects of Eplerenone. Circulation 106, 2848-2853.
20. Malliani A (2000) Principle of Cardiovascular Neural Regulation in Health and Disease. Kluwer Academic Publishers, Boston.
21. Mitani F, Mukai K, Ogawa T, et al. (1997) Expression of cytochromes P450ado and P45011beta in rat adrenal gland during late gestational and neonatal stages. Steroids 62, 57-61.
22. Mizuno Y, Yoshimura M, Yasue H, et al. (2001) Aldosterone production is activated in failing ventricle in humans. Circulation 103, 72-77.
23. Nicoletti A and Michel JB (1999) Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovascular Research 41, 532-543.
24. Pitt B (1995) 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovascular Drugs Therapy 9, 145-149.
25. Pitt B, Remme W, Zannad F, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 348, 1309-1321.
26. Pitt B, Zannad F, Remme WJ, et al. for the Randomized Aldactone Evaluation Study Investigators (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine 341, 709-717.
27. Ramires FJA, Mansur A, Coelho O, et al. (2000) Effect of spironolactone on ventricular arrythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. American Journal of Cardiology 85, 1207-1211.
28. Robert V, Thiem NV, Cheav SL, et al. (1994) Increased cardiac collagens (I) and (III) mRNAs in aldosterone-salt hypertension. Hypertension 24, 30-36.
29. Robert V, Silvestre JS, Charlemagne D, et al. (1995) Biological determinants of aldosterone-induced cardiac fibrosis in rat. Hypertension 26, 971-978.
30. Robert V, Besse S, Sabri A, et al. (1997) Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Laboratory Investigation 76, 729-738.
31. Robert V, Heymes C, Silvestre JS, et al. (1999) Angiotensin AT1 receptor subtype as a cardiac target of aldosterone; role in aldosterone-salt induced fibrosis. Hypertension 33, 981-986.
32. Rocha R and Stier CT (2001) Pathophysiological effects of aldosterone in cardiovascular tissues. Trends in Endocrinology and Metabolism 12, 308-314.
33. Rocha R and Funder JW (2002) The pathophysiology of aldosterone in the cardiovascular system. Annals of the New York Academy Science 970, 89-100.
34. Rocha R, Rudolph AE, Frierdich GE, et al. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. American Journal of Physiology. Heart and Circulatory Physiology 283, H1802-H1810.
35. Sato A, Liu JP and Funder JW (1997) Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro. Endocrinology 138, 3410-3416.
36. Satoh M, Nakamura M, Saitoh H, et al. (2002) Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clinical Science (London) 102, 381-386.
37. Silvestre J, Heymes C, Oubenaissa A, et al. (1999) Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99, 2694-2701.
38. Silvestre JS, Robert V, Heymes C, et al. (1998) Myocardial production of aldosterone and corticosterone in the rat. Physiological Regulations. Journal of Biological Chemistry 273, 4883-4891.
39. Silvestre JS, Robert V, Escoubet E, et al. (2000) Different regulation of cardiac and renal corticosteroid receptors in aldosterone-salt treated rats; effect of hypertension and glucocorticoids. Journal of Molecular and Cellular Cardiology 32, 1249-1253.
40. Simpson SAS and Tait JF (1953) Physicochemical methods of detection of a previously unidentified adrenal hormone. Memoirs of the Society of Endocrinologist 2, 9-24.
41. Sun Y, Zhang J, Lu L, et al. (2002) Aldosterone-induced inflammation in the rat heart. American Journal of Pathology 161, 1773-1781.
42. Swynghedauw B (2000) Myocardial remodelling: pharmacological targets. Expert Opinion on Investigative Drugs 11, 661-674.
43. Takeda Y, Miyamori I, Inaba S, et al. (1997) Vascular aldosterone in genetically hypertensive rats. Hypertension 29, 45-48.
44. Takeda Y, Yoneda T, Demura M, et al. (2000) Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 141, 1901-1904.
45. Urata H, Boehm KD, Philip A, et al. (1993) Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. Journal ofClinical Investigation 91, 1269-1281.
46. Virdis A, Neves MF, Amiri F, et al. (2002) Spironolactone improves angiotensininduced vascular changes and oxidative stress. Hypertension 40, 504-510.
47. Weber KT (2000) Recruitable ACE and tissue repair in the infarcted heart. Journal of the Renin Angiotensin Aldosterone System 1, 295-303.
48. Weber KT (2001) Aldosterone in congestive heart failure. New England Journal of Medicine 345, 1689-1697.
49. Wotus C, Levay-Young BK, Rogers LM, et al. (1998) Development of adrenal zonation in fetal rats defined by expression of aldosterone synthase and 11betahydroxylase. Endocrinology 139, 4397-4403.
50. Young M, Head G and Funder J (1995) Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. American Journal of Physiology 269, E657-E662.
51. Zannad F, Alla F, Dousset B, et al. (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102, 2700-2706.